• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Pembrolizumab combined with lenalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE-023 study.

作者信息

Mateos Maria-Victoria, Orlowski Robert Z, Ocio Enrique M, Rodríguez-Otero Paula, Reece Donna, Moreau Philippe, Munshi Nikhil, Avigan David E, Siegel David S, Ghori Razi, Farooqui Mohammed Z H, Marinello Patricia, San-Miguel Jesus

机构信息

Complejo Asistencial Universitario de Salamanca/IBSAL & Centro de Investigación del Cáncer (IBMCC-CSIC-USAL), Salamanca, Spain.

The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

出版信息

Br J Haematol. 2019 Sep;186(5):e117-e121. doi: 10.1111/bjh.15946. Epub 2019 May 15.

DOI:10.1111/bjh.15946
PMID:31090915
Abstract
摘要

相似文献

1
Pembrolizumab combined with lenalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE-023 study.帕博利珠单抗联合来那度胺及低剂量地塞米松治疗复发或难治性多发性骨髓瘤：I期KEYNOTE-023研究
Br J Haematol. 2019 Sep;186(5):e117-e121. doi: 10.1111/bjh.15946. Epub 2019 May 15.
2
Elotuzumab in Combination with Lenalidomide and Dexamethasone for Treatment-resistant Immunoglobulin Light Chain Amyloidosis With Multiple Myeloma.埃罗妥珠单抗联合来那度胺和地塞米松治疗难治性免疫球蛋白轻链淀粉样变性伴多发性骨髓瘤
Clin Lymphoma Myeloma Leuk. 2019 Jan;19(1):e33-e36. doi: 10.1016/j.clml.2018.08.021. Epub 2018 Sep 5.
3
Elotuzumab in the treatment of relapsed and refractory multiple myeloma.依洛尤单抗治疗复发/难治性多发性骨髓瘤。
Future Oncol. 2021 May;17(13):1581-1591. doi: 10.2217/fon-2020-1088. Epub 2021 Jan 22.
4
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial.帕博利珠单抗联合泊马度胺和地塞米松治疗复发或难治性多发性骨髓瘤患者（KEYNOTE-183）：一项随机、开放标签的3期试验。
Lancet Haematol. 2019 Sep;6(9):e459-e469. doi: 10.1016/S2352-3026(19)30110-3. Epub 2019 Jul 18.
5
Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial.帕博利珠单抗联合来那度胺和地塞米松用于初治多发性骨髓瘤患者（KEYNOTE-185）：一项随机、开放标签的3期试验。
Lancet Haematol. 2019 Sep;6(9):e448-e458. doi: 10.1016/S2352-3026(19)30109-7. Epub 2019 Jul 18.
6
Pembrolizumab, lenalidomide and dexamethasone post autologous transplant in patients with high-risk multiple myeloma.帕博利珠单抗、来那度胺和地塞米松用于高危多发性骨髓瘤患者自体移植后治疗
Am J Hematol. 2021 Nov 1;96(11):E430-E433. doi: 10.1002/ajh.26333. Epub 2021 Sep 17.
7
Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study.埃罗妥珠单抗联合来那度胺和地塞米松治疗复发多发性骨髓瘤患者：随机、开放标签、1b-2期剂量递增研究的最终2期结果
Lancet Haematol. 2015 Dec;2(12):e516-27. doi: 10.1016/S2352-3026(15)00197-0. Epub 2015 Nov 16.
8
A critical evaluation of pembrolizumab in addition to lenalidomide and dexamethasone for the treatment of multiple myeloma.帕博利珠单抗联合来那度胺和地塞米松治疗多发性骨髓瘤的疗效评价。
Expert Rev Hematol. 2020 May;13(5):435-445. doi: 10.1080/17474086.2020.1744432. Epub 2020 Mar 21.
9
Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.卡非佐米、来那度胺和地塞米松治疗复发或难治性多发性骨髓瘤患者的总生存期改善。
J Clin Oncol. 2018 Mar 10;36(8):728-734. doi: 10.1200/JCO.2017.76.5032. Epub 2018 Jan 17.
10
[Carfilzomib, lenalidomide, and dexamethasone therapy for refractory and relapsed multiple myeloma: a single-center study of 29 patients].卡非佐米、来那度胺和地塞米松治疗难治性和复发性多发性骨髓瘤：29例患者的单中心研究
Rinsho Ketsueki. 2018;59(6):698-700. doi: 10.11406/rinketsu.59.698.

引用本文的文献

1
CD34 and CD34 MM cells show different immune-checkpoint molecule expression profiles: high expression of CD112 and CD137 ligand on CD34 MM cells.CD34阳性和CD34阴性多发性骨髓瘤细胞显示出不同的免疫检查点分子表达谱：CD34阳性多发性骨髓瘤细胞上CD112和CD137配体高表达。
Int J Hematol. 2025 Jan;121(1):89-99. doi: 10.1007/s12185-024-03867-0. Epub 2024 Nov 12.
2
Multiple myeloma and the potential of new checkpoint inhibitors for immunotherapy.多发性骨髓瘤与新型免疫检查点抑制剂的免疫治疗潜力
Ther Adv Vaccines Immunother. 2024 Oct 9;12:25151355241288453. doi: 10.1177/25151355241288453. eCollection 2024.
3
Cytokine-induced killer cells: new insights for therapy of hematologic malignancies.
细胞因子诱导的杀伤细胞：恶性血液病治疗的新见解。
Stem Cell Res Ther. 2024 Aug 13;15(1):254. doi: 10.1186/s13287-024-03869-z.
4
Multiple myeloma: signaling pathways and targeted therapy.多发性骨髓瘤：信号通路与靶向治疗。
Mol Biomed. 2024 Jul 4;5(1):25. doi: 10.1186/s43556-024-00188-w.
5
Immune checkpoint blockade in hematological malignancies: current state and future potential.血液系统恶性肿瘤中的免疫检查点阻断：现状与未来潜力
Front Oncol. 2024 Jan 23;14:1323914. doi: 10.3389/fonc.2024.1323914. eCollection 2024.
6
Targeted immunotherapy: harnessing the immune system to battle multiple myeloma.靶向免疫疗法：利用免疫系统对抗多发性骨髓瘤。
Cell Death Discov. 2024 Jan 27;10(1):55. doi: 10.1038/s41420-024-01818-6.
7
All-cause and immune checkpoint inhibitor-associated acute kidney injury in immune checkpoint inhibitor users: a meta-analysis of occurrence rate, risk factors and mortality.免疫检查点抑制剂使用者中全因性和免疫检查点抑制剂相关急性肾损伤：发生率、危险因素及死亡率的荟萃分析
Clin Kidney J. 2023 Nov 28;17(1):sfad292. doi: 10.1093/ckj/sfad292. eCollection 2024 Jan.
8
Checkpoint inhibition in hematologic malignancies.血液系统恶性肿瘤中的检查点抑制
Front Oncol. 2023 Oct 17;13:1288172. doi: 10.3389/fonc.2023.1288172. eCollection 2023.
9
Multiplex immunohistochemistry elucidates increased distance between cytotoxic T cells and plasma cells in relapsed myeloma, and identifies Lag-3 as the most common checkpoint receptor on cytotoxic T cells of myeloma patients.多重免疫组化阐明了复发性骨髓瘤中细胞毒性 T 细胞和浆细胞之间距离的增加，并确定了 Lag-3 为骨髓瘤患者细胞毒性 T 细胞上最常见的检查点受体。
Haematologica. 2024 May 1;109(5):1487-1500. doi: 10.3324/haematol.2023.283344.
10
High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma.高表达的 NEK2 在髓系祖细胞中抑制多发性骨髓瘤中的 T 细胞免疫。
Cell Rep Med. 2023 Oct 17;4(10):101214. doi: 10.1016/j.xcrm.2023.101214. Epub 2023 Oct 3.